Hanson Pharmaceuticals (03692): The treatment of small cell lung cancer with injectable Ruikang rivoltamab (HS-20093) is included in the priority review and approval process of the State Drug Administration

According to Zhitong Finance App, Hanson Pharmaceuticals (03692) announced that on August 21, 2026, based on the positive results of the critical phase III trial ARTEMIS-008 of Ruikang rivoltamab (HS-20093) (this product), the product's indications for small cell lung cancer that failed platinum-containing treatment were included in the China National Drug Administration (NMPA) priority review and approval process.